I thought about calling this “PSA” but I thought that might just appeal to potential customers for Dendreon’s customized vaccine, Provenge.
No, this is about mREITs. Read the rest of this entry »
Last night’s question from Dan led to a fairly technical and complicated answer about the current state of the mREIT sector.
Again without giving specific investment advice (since I have no idea what your specific circumstances are), I thought I’d put into words a little technical primer on picking up bargains when the market gods are slamming these stocks.
I’ll try to describe how I pick them, leaving how my emotional and financial state affects my order of choice for another time. Just be aware that your own ability to sleep at night, or need for cash, can radically change your order of preference among these stocks. Right now, I’d say the fear factor has driven a lot of small investors to sell, simply because they don’t like the sickening feeling of seeing red pixels on their screen full of stock prices. Read the rest of this entry »
Annaly (NLY) took a big step last week toward becoming an ETF all by itself.
Under replacement CEO Wellington Denahan-Norris (formerly Chief Investment Officer and then co-CEO as Mike Farrell fought his cancer), Annaly decided to bid for all the shares of its commercial mortgage REIT, CreXus (CXS). They already owned a majority share, and already provided a significant piece of Crexus’ financing, so the exposure hasn’t really changed much for the monster (over $140 billion in assets) Agency MBS REIT, Annaly.
It makes economic sense for a mortgage REIT to buy its stock whenever it trades significantly below book value, since that increases the yield for existing shareholders and supports the stock price. The negative is that it decreases the capital supporting the portfolio. In this case, the $840 million price tag for the commercial mortgage REIT is less than NLY gets in principal paydown every month from its Agency MBS portfolio. Read the rest of this entry »